CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

被引：0

作者：

Yu Sunakawa

Akihito Tsuji

Tadamichi Denda

Yoshihiko Segawa

Yuji Negoro

Ken Shimada

Mitsugu Kochi

Masato Nakamura

Masahito Kotaka

Hiroaki Tanioka

Akinori Takagane

Satoshi Tani

Tatsuro Yamaguchi

Takanori Watanabe

Masahiro Takeuchi

Masashi Fujii

Wataru Ichikawa

机构：

[1] St. Marianna University School of Medicine,Department of Clinical Oncology

[2] Kagawa University Faculty of Medicine Cancer Center,Department of Clinical Oncology

[3] Kagawa University Hospital,Division of Gastroenterology

[4] Chiba Cancer Center,Department of Medical Oncology

[5] International Medical Center,Department of Gastroenterology

[6] Saitama Medical University,Division of Medical Oncology, Department of Internal Medicine

[7] Kochi Health Sciences Center,Department of Digestive Surgery

[8] Showa University Koto Toyosu Hospital,Aizawa Comprehensive Cancer Center

[9] Nihon University School of Medicine,Gastrointestinal Cancer Center

[10] Aizawa Hospital,Department of Medical Oncology

[11] Sano Hospital,Department of Surgery

[12] Japan Labour Health and Welfare Organization Okayama Rosai Hospital,Department of Internal Medicine

[13] Hakodate Goryoukaku Hospital,Department of Surgery

[14] Konan Hospital,Department of Surgery

[15] Tokyo Metropolitan Cancer and Infections diseases Center Komagome Hospital,Department of Clinical Medicine (Biostatistics)

[16] Himeji Red Cross Hospital,Division of Medical Oncology

[17] Kitasato University School of Pharmacy,undefined

[18] Showa University Fujigaoka Hospital,undefined

来源：

Targeted Oncology | 2017年 / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：787 / 794

页数：7

共 50 条

[1] CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer
Sunakawa, Yu
Tsuji, Akihito
Denda, Tadamichi
Segawa, Yoshihiko
Negoro, Yuji
Shimada, Ken
Kochi, Mitsugu
Nakamura, Masato
Kotaka, Masahito
Tanioka, Hiroaki
Takagane, Akinori
Tani, Satoshi
Yamaguchi, Tatsuro
Watanabe, Takanori
Takeuchi, Masahiro
Fujii, Masashi
Ichikawa, Wataru
TARGETED ONCOLOGY, 2017, 12 (06) : 787 - 794
[2] CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials.
Sunakawa, Yu
Ichikawa, Wataru
Tsuji, Akihito
Denda, Tadamichi
Segawa, Yoshihiko
Negoro, Yuji
Shimada, Ken
Kochi, Mitsugu
Nakamura, Masato
Kotaka, Masahito
Tanioka, Hiroaki
Takagane, Akinori
Tani, Satoshi
Yamaguchi, Tatsuro
Takeuchi, Masahiro
Fujii, Masashi
Nakajima, Toshifusa
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[3] CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Ubago, R.
Castillo, M. A.
Flores, S.
Rodriguez, R.
Beltran, C.
VALUE IN HEALTH, 2011, 14 (07) : A433 - A434
[4] Cetuximab for the first-line treatment of metastatic colorectal cancer
Meads, C.
Round, J.
Tubeuf, S.
Moore, D.
Pennant, M.
Baylis, S.
HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 8
[5] Role of cetuximab in first-line treatment of metastatic colorectal cancer
Miguel Jhonatan Sotelo
Beatriz García-Paredes
Carlos Aguado
Javier Sastre
Eduardo Díaz-Rubio
World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
[6] Role of cetuximab in first-line treatment of metastatic colorectal cancer
Sotelo, Miguel Jhonatan
Garcia-Paredes, Beatriz
Aguado, Carlos
Sastre, Javier
Diaz-Rubio, Eduardo
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
[7] Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
Tamotsu Sagawa
Yasushi Sato
Masahiro Hirakawa
Kyoko Hamaguchi
Akira Fukuya
Koichi Okamoto
Hiroshi Miyamoto
Naoki Muguruma
Koshi Fujikawa
Yasuo Takahashi
Tetsuji Takayama
Scientific Reports, 10
[8] Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
Sagawa, Tamotsu
Sato, Yasushi
Hirakawa, Masahiro
Hamaguchi, Kyoko
Fukuya, Akira
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Fujikawa, Koshi
Takahashi, Yasuo
Takayama, Tetsuji
SCIENTIFIC REPORTS, 2020, 10 (01)
[9] CETUXIMAB IN COMBINATION WITH XELIRI OR XELOX IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Ocvirk, Janja
Rebersek, Martina
Boc, Marko
Mesti, Tanja
Moltara, Maja Ebert
ANNALS OF ONCOLOGY, 2011, 22 : v96 - v96
[10] First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab
Tonini, Giuseppe
Calvieri, Alice
Vincenzi, Bruno
Santini, Daniele
ONCOTARGETS AND THERAPY, 2009, 2 : 73 - 82

← 1 2 3 4 5 →